# CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

> **NCT05143996** · PHASE1 · RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** CLN-049

## Key facts

- **NCT ID:** NCT05143996
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2027-01
- **Final completion:** 2027-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143996, "CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05143996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*